The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

The US Food and Drug Administration (FDA) has granted priority review to durvalumab for the treatment of patients with resectable, stage II-IVA gastric or gastroesophageal junction (GEJ) cancer.

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) in adults with advanced or unresectable hepatocellular carcinoma (HCC). The ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...